Skip to content
Back to Blog
Bio
2026-04-138 min read68

Biosimilar Third Wave: SME Market Entry Strategies in the 2026 Patent Cliff Era

With 200+ blockbuster patents expiring from 2026, the biosimilar 'third wave' is in full swing. We analyze five market entry strategies for SME biotech companies amid regulatory innovations including Phase 3 waivers and accelerated review timelines.

KITIM Consulting Team

The Biosimilar 'Third Wave' of 2026 — Opportunities from the Patent Cliff

The global biopharmaceutical market is approaching an unprecedented inflection point. Between 2025 and 2030, patents on more than 200 blockbuster biologics will expire, with revenue exposure exceeding $236 billion. The so-called 'third wave of biosimilars' is now fully underway.

Key products approaching patent expiry include:

  • Daratumumab (Darzalex): Patent expiry in 2026, annual sales ~$10.3 billion
  • Pembrolizumab (Keytruda): Patent expiry in 2028, annual sales ~$25 billion — the highest-grossing drug in history
  • Ustekinumab (Stelara): U.S. patent expiry in 2025, annual sales ~$10.7 billion
  • Aflibercept (Eylea): Patent expiry in 2027, poised to open the ophthalmic biosimilar market
  • What makes this even more striking is the pipeline gap in the U.S. market. Of approximately 120 reference biologics listed with the FDA, 106 products (roughly 90%) have no biosimilar pipeline whatsoever. This represents vast white space — a first-mover opportunity for agile small and mid-sized biotech firms.

    Regulatory Innovation — Phase 3 Waivers and Accelerated Review

    The regulatory landscape, historically the tallest barrier to biosimilar development, is undergoing transformative change starting in 2026.

    Global Regulatory Developments

  • U.S. FDA: Guidelines formally enabling Phase 3 clinical trial waivers for biosimilars with robust analytical similarity data take full effect in 2026, potentially saving 2–3 years and tens of millions of dollars in development costs.
  • European EMA: Already operating an analytically-driven approval framework, with additional flexibility on immunogenicity comparability studies from 2026.
  • Korea MFDS: Biosimilar review timelines have been reduced from 420 to 295 days, with dedicated review teams assigned by product category to improve predictability.
  • These regulatory reforms are expected to lower biosimilar development costs from the historical 70–80% of originator costs to below 50%, meaningfully reducing the capital threshold for market entry by smaller firms.

    Five Market Entry Strategies for SME Biotech Companies

    1. Leverage CDMOs to Minimize Manufacturing Investment

    Building a biologics manufacturing facility typically requires investments of $200–400 million or more. SMEs can strategically utilize CDMOs (Contract Development and Manufacturing Organizations) to minimize upfront capital requirements. Korea's upcoming CDMO Special Act, expected to take effect in 2026, will provide tax incentives and streamlined regulatory pathways for CDMO-based production, further improving the economics of outsourced manufacturing.

    2. Target Uncontested Niche Products

    Large biosimilar companies tend to concentrate on the top 10 revenue-generating biologics. Meanwhile, mid-tier products with $1–3 billion in annual sales and specialty indications in ophthalmology or rare diseases face limited competition. Systematically screening the 106 pipeline-free products for alignment with existing technology platforms is critical.

    3. Global Expansion Through Licensing and Partnerships

    Rather than building proprietary commercial infrastructure abroad, technology licensing and co-development partnerships offer a capital-efficient route to global markets. Southeast Asian and Latin American markets, where biosimilar demand is surging, have shown strong interest in Korean biotech capabilities.

    4. Maximize Government R&D Funding

  • Bio & Medical Technology Development Programs: Support for core enabling technologies such as analytical method development and cell line engineering
  • Biopharmaceutical Supply Chain Stability Programs: Funding for raw material localization and process optimization
  • Global Market Entry Support: Coverage for overseas clinical costs, regulatory consulting, and local partner matching
  • With strategic planning from the proposal stage, companies can cover 50–75% of development costs through government grants.

    5. Proactive GMP Certification Preparation

    GMP compliance remains the final gateway to biosimilar commercialization. Companies should actively utilize the MFDS pre-consultation system to incorporate GMP requirements from the facility design stage and engage with the Global GMP Implementation Technology Support Consortium to simultaneously meet U.S. cGMP and EU GMP standards.

    KITIM Consulting — Biosimilar Commercialization Support

    KITIM provides end-to-end support for SME biotech companies preparing to enter the biosimilar market, including GMP certification consulting, international regulatory strategy, government R&D grant applications and project planning, and business plan development and investment strategy. The window of opportunity created by the patent cliff is finite. Connect with our experts today to build your market entry strategy.

    Contact: [Schedule a Consultation](/en/contact) | Free consultation available

    BiosimilarPatentCliffPhase3ExemptionCDMOSMEMarketEntry

    Related Posts

    Bio

    Biologics Approval Fees Rise From KRW 8.03M to 20.71M, Data-Submission Drugs About 6x — MFDS Fee Regulation Amendment Pre-Announced Nov 6, 2026 (Comments Due Nov 26 / Dec 16): Filing Timing, Budget Review and Fee-Reduction Checks for Pharma & Bio SMEs

    Under the fee amendment MFDS proposed on November 6, approval fees for new biologics would rise from KRW 8.03 million to KRW 20.71 million, and fees for data-submission drugs would go up about sixfold. This guide shows pharma and bio SMEs how to review their filing timing, budgets, fee-reduction eligibility and public comments.

    2026-11-09
    Management Consulting

    Factories With 20–49 Workers Will Need a Safety or Health Manager — Korea's First Tripartite Agreement on November 5 (About 30,000 Sites in 5 Industries Including Manufacturing, Decree Amendment in 2027, Target Start 2028), the Owner-Led Alternative and Government Payroll Support: A Preparation Guide for Small Manufacturers

    Under Korea's November 5 tripartite agreement, about 30,000 sites with 20–49 workers in manufacturing and four other industries are expected to need a qualified safety or health manager from 2028. This guide covers what is settled and what is still open, the owner-led alternative, a cost comparison, and a preparation checklist.

    2026-11-09
    Government Programs

    SMEs Can Now Enter the KRW 1,500 Trillion 'Mega Project' Supply Chain from the Design Stage — MSS Joins as a Lead Ministry, Large/Mid-Tier–SME Councils and Regional Councils Launch (Nov 6 Plan to Expand Planning-Stage Participation), and How SMEs Targeting Semiconductor, AI Data Center and Physical AI Supply Chains Should Prepare Validation, Certification and Mass-Production Qualification

    MSS has joined Korea's KRW 1,500 trillion mega projects as a lead ministry and plans to bring SMEs in from the planning stage. This guide covers how the central and regional councils will work and how to line up support programs against the validation, certification and mass-production barriers.

    2026-11-09
    Updated daily

    Let AI find government support programs in this field

    Complete a 3-minute company assessment and we will recommend programs that fit your company, each with a match score. It is free.

    Get AI-Matched Programs for Free

    Need Consulting?

    Our technology innovation consultants will propose the optimal solution for your company.